{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03598608",
            "orgStudyIdInfo": {
                "id": "4280-003"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-4280-003",
                    "type": "OTHER",
                    "domain": "Merck"
                },
                {
                    "id": "2023-503587-17-00",
                    "type": "REGISTRY",
                    "domain": "EU CT"
                },
                {
                    "id": "U1111-1287-5405",
                    "type": "REGISTRY",
                    "domain": "UTN"
                },
                {
                    "id": "2018-001461-16",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",
            "officialTitle": "A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-to-evaluate-the-safety-and-efficacy-of-a-combination-of-favezelimab-mk-and-pembrolizumab-mk-in-participants-with-hematologic-malignancies-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-10-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-04-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-04-19",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-07-16",
            "studyFirstSubmitQcDate": "2018-07-16",
            "studyFirstPostDateStruct": {
                "date": "2018-07-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies:\n\n* classical Hodgkin lymphoma (cHL)\n* diffuse large B-cell lymphoma (DLBCL)\n* indolent non-Hodgkin lymphoma (iNHL)\n\nThis study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomized study design.\n\nThe study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RP2D) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.\n\nThere is no primary hypothesis for this study."
        },
        "conditionsModule": {
            "conditions": [
                "Hodgkin Disease",
                "Lymphoma, Non-Hodgkin",
                "Lymphoma, B-Cell"
            ],
            "keywords": [
                "programmed cell death 1 (PD-1, PD1)",
                "programmed cell death ligand 1 (PD-L1, PDL1)",
                "programmed cell death ligand 2 (PD-L2, PDL2)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Participants in Part B: Randomized cHL-Monotherapy arm in the study will be randomized (1:1 ratio) to receive pembrolizumab or favezelimab."
                }
            },
            "enrollmentInfo": {
                "count": 174,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Favezelimab Dose A+pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part A: Favezelimab Dose B+pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part A: Favezelimab Dose C+Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part B: cHL-Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the recommended Phase 2 dose (RP2D) of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part B: DLBCL-Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part B: iNHL-Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                },
                {
                    "label": "Part B: Randomized cHL-Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with cHL receive either pembrolizumab by IV infusion or the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).",
                    "interventionNames": [
                        "Biological: pembrolizumab",
                        "Biological: Favezelimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "pembrolizumab",
                    "description": "Administered as an IV infusion every 3 weeks (Q3W)",
                    "armGroupLabels": [
                        "Part A: Favezelimab Dose A+pembrolizumab",
                        "Part A: Favezelimab Dose B+pembrolizumab",
                        "Part A: Favezelimab Dose C+Pembrolizumab",
                        "Part B: DLBCL-Combination Therapy",
                        "Part B: Randomized cHL-Monotherapy",
                        "Part B: cHL-Combination Therapy",
                        "Part B: iNHL-Combination Therapy"
                    ],
                    "otherNames": [
                        "KEYTRUDA\u00ae",
                        "MK-3475"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Favezelimab",
                    "description": "Administered as an IV infusion Q3W",
                    "armGroupLabels": [
                        "Part A: Favezelimab Dose A+pembrolizumab",
                        "Part A: Favezelimab Dose B+pembrolizumab",
                        "Part A: Favezelimab Dose C+Pembrolizumab",
                        "Part B: DLBCL-Combination Therapy",
                        "Part B: Randomized cHL-Monotherapy",
                        "Part B: cHL-Combination Therapy",
                        "Part B: iNHL-Combination Therapy"
                    ],
                    "otherNames": [
                        "MK-4280"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)",
                    "description": "DLT will be defined as any drug-related adverse event (AE) observed during the DLT evaluation period (Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle and reported as the percentage of participants experiencing a DLT defined by the National Cancer Institute Common Terminology for Adverse Events version 4.0.",
                    "timeFrame": "Cycle 1 (up to 21 days)"
                },
                {
                    "measure": "Percentage of Participants Experiencing an Adverse Event (AE)",
                    "description": "Percentage of participants experiencing an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment",
                    "timeFrame": "From time of signing informed consent form (ICF) until the end of follow-up (up to approximately 27 months)"
                },
                {
                    "measure": "Percentage of Participants with Treatment Discontinuations Due to an AE",
                    "description": "Percentage of participants discontinuing study treatment due to an AE",
                    "timeFrame": "From time of signing informed consent form (ICF) until the end of study treatment (up to approximately 24 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per lymphoma disease response criteria (Cheson et. al., 2007) as assessed by the investigator.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Serum Concentration of Favezelimab",
                    "description": "Blood samples will be collected at designated time points for the determination of the serum concentration of favezelimab. For Cycles 1 and 8: Day 1 at predose, end of infusion, and 4 hours postdose; Days 8 and 15 at any time. Cycles 2 through 7, Cycles 9 through 16 and every 4 cycles thereafter: Day 1 at predose. Blood samples will also be collected at the 30-day follow-up visit.",
                    "timeFrame": "At designated time points (Up to approximately 25 months)"
                },
                {
                    "measure": "Serum Concentration of Pembrolizumab",
                    "description": "Blood samples will be collected at designated time points for the determination of the serum concentration of pembrolizumab. For Cycles 1 and 8: Day 1 at predose, end of infusion, and 4 hours postdose; Days 8 and 15 at any time. Cycles 2 through 7, Cycles 9 through 16 and every 4 cycles thereafter: Day 1 at predose. Blood samples will also be collected at the 30-day follow-up visit.",
                    "timeFrame": "At designated time points (Up to approximately 25 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has measurable disease, defined as \u22651 lesion that can be accurately measured in 2 dimensions with diagnostic quality cross sectional anatomic imaging (computed tomography or magnetic resonance imaging). Minimum measurement must be \\>15 mm in the longest diameter or \\>10 mm in the short axis\n* Is able to provide a core or excisional tumor biopsy for biomarker analysis from an archival (within 3 months) or newly obtained biopsy at screening\n* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)\n\nExclusion Criteria:\n\n* Has known clinically active central nervous system (CNS) involvement\n* Has received prior therapy with an anti-lymphocyte activation gene-3 (LAG-3) antibody\n* Has received chimeric antigen receptors (CAR)-T-cell therapy for cHL and DLBCL Cohorts\n* Has received prior anticancer therapy or thoracic radiation therapy within 14 days before the first dose of study treatment\n* Has \u2265Grade 2 non-hematological residual toxicities from prior therapy\n* Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264Grade 1 or at baseline) from AEs due to agents administered \u22654 weeks earlier\n* Has received a live vaccine within 30 days prior to first dose of study treatment. Administration of killed vaccines are allowed\n* Has received an investigational agent or used an investigational device within 4 weeks prior to intervention administration\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug\n* Has a known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\n* Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n* Has an active infection requiring intravenous systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has known, active hepatitis B or hepatitis C infection\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment\n* Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the last 5 years",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Banner MD Anderson Cancer Center ( Site 0020)",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "480-256-3425"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "City of Hope ( Site 0001)",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "626-256-2405"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "310-582-4067"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Pacific Cancer Care ( Site 0006)",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Monterey",
                    "state": "California",
                    "zip": "93940",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.60024,
                        "lon": -121.89468
                    }
                },
                {
                    "facility": "University of California San Francisco ( Site 0023)",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "415-885-3882"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute ( Site 0002)",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Fox Chase Cancer Center ( Site 0019)",
                    "status": "COMPLETED",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Texas Oncology-Austin Midtown ( Site 8002)",
                    "status": "COMPLETED",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Concord Repatriation & General Hospital ( Site 0203)",
                    "status": "RECRUITING",
                    "city": "Concord",
                    "state": "New South Wales",
                    "zip": "2139",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+61397677341"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.84722,
                        "lon": 151.10381
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital ( Site 0204)",
                    "status": "RECRUITING",
                    "city": "Woollongabba",
                    "state": "Queensland",
                    "zip": "4102",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+61731766826"
                        }
                    ]
                },
                {
                    "facility": "Monash Health ( Site 0201)",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3168",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+61395946666"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "St Vincent s Hospital (Melbourne) Limited ( Site 0202)",
                    "status": "RECRUITING",
                    "city": "Fitzroy",
                    "state": "Victoria",
                    "zip": "3065",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+61398593936"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.79839,
                        "lon": 144.97833
                    }
                },
                {
                    "facility": "BC Cancer ( Site 0107)",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z 1L3",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "6048776000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "CancerCare Manitoba ( Site 0101)",
                    "status": "RECRUITING",
                    "city": "Winnipeg",
                    "state": "Manitoba",
                    "zip": "R3E 0V9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "2047874156"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.8844,
                        "lon": -97.14704
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre ( Site 0100)",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "4169464501"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Jewish General Hospital ( Site 0105)",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "5143408222 x 24572"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "U. klinikum Koeln AOER ( Site 0326)",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Koeln",
                    "state": "Nordrhein-Westfalen",
                    "zip": "50937",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.93333,
                        "lon": 6.95
                    }
                },
                {
                    "facility": "Universitaetsklinikum Leipzig AOeR ( Site 0327)",
                    "status": "RECRUITING",
                    "city": "Leipzig",
                    "state": "Sachsen",
                    "zip": "4103",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+493419720363"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "Rambam Medical Center ( Site 0382)",
                    "status": "RECRUITING",
                    "city": "Haifa",
                    "zip": "3109601",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+97247773109"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                },
                {
                    "facility": "Hadassah Ein Karem Jerusalem ( Site 0383)",
                    "status": "RECRUITING",
                    "city": "Jerusalem",
                    "zip": "9112001",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+97226778243"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Chaim Sheba Medical Center. ( Site 0380)",
                    "status": "RECRUITING",
                    "city": "Ramat Gan",
                    "zip": "5262001",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+97235302588"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Sourasky Medical Center ( Site 0381)",
                    "status": "RECRUITING",
                    "city": "Tel Aviv",
                    "zip": "6423906",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+97236973782"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351)",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "state": "Emilia-Romagna",
                    "zip": "40138",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+390516363680"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354)",
                    "status": "RECRUITING",
                    "city": "Meldola",
                    "state": "Forli-Cesena",
                    "zip": "47014",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+390543739290"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352)",
                    "status": "RECRUITING",
                    "city": "Rozzano",
                    "state": "Milano",
                    "zip": "20089",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+390282244080"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.38193,
                        "lon": 9.1559
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "https://www.merckclinicaltrials.com/"
                },
                {
                    "label": "Plain Language Summary",
                    "url": "https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=4280-003&kw=4280-003"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                },
                {
                    "id": "D000006689",
                    "term": "Hodgkin Disease"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Lymphoma, Non-Hodgkin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "Lymphoma, B-Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6845",
                    "name": "Death",
                    "relevance": "LOW"
                },
                {
                    "id": "M9751",
                    "name": "Hodgkin Disease",
                    "asFound": "Hodgkin's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "Lymphoma, B-Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2817",
                    "name": "Hodgkin Lymphoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}